We have developed a simple to use COVID-19 molecular diagnostic test which can be used in clinical laboratories to process patient samples and to detect those positive for COVID-19.
We have since extended this development to include other common flu season pathogens, such as Influenza and RSV in our test, to support effective screening and triage of symptomatic patients. With the support of our network across Europe we will be conducting clinical studies to determine the utility and effectiveness of adopting these assays into the healthcare system, such as the NHS. Whilst COVID development is a top priority, GeneFirst continues to develop and launch oncology tests for use with liquid biopsies, and to grow the team as part of the business plan for expansion. – Winnie Wu, CEO GeneFirst Limited